Published: 12 November 2025
Author(s): Mauro Gori, Luca Fazzini, Jennifer Meessen, Raul Limonta, Samuela Carigi, Matteo Bianco, Luisa De Gennaro, Concetta Di Nora, Paolo Manca, Maria Vittoria Matassini, Vittoria Rizzello, Denitza Tinti, Aldo Pietro Maggioni, Francesco Orso, Marco Gorini, Renata De Maria, Italian Network on Heart Failure (IN-HF) Investigators
Section: Original Article
Dihydropyridine calcium channel blockers (DHP-CCB) are widely used in heart failure (HF), despite the lack of data regarding their safety, especially in patients with reduced ejection fraction (HFrEF). We aimed to evaluate DHP-CCB prescription trends over time, their association with GDMT uptake and related outcomes across the spectrum of EF.
